{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:27Z","timestamp":1780920687621,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":91,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101200","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:57:42Z","timestamp":1775231862000},"page":"101200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Feasibility of quality indicators to assess the prevalence of guideline adherence in a german cohort of patients with advanced or metastatic breast cancer: Results of the BRE-BY-MED study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-5402","authenticated-orcid":false,"given":"Lilly Sophia","family":"Brandstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"M\u00fcller-Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-2552","authenticated-orcid":false,"given":"Jens-Peter","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-3515","authenticated-orcid":false,"given":"Peter U","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-9666","authenticated-orcid":false,"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctarc.2026.101200_bib0001","first-page":"19","article-title":"Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Cardoso","year":"2012","journal-title":"Off. J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/cco.2018.05.01","article-title":"Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?","volume":"7","author":"Hattori","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101200_bib0003","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-leitlinie fr\u00fcherkennung, diagnose, therapie und nachsorge des mammakarzinoms. In., vol. Version 4.3; (2020)."},{"key":"10.1016\/j.ctarc.2026.101200_bib0004","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V., der Deutschen Krebsgesellschaft e. V. und der stiftung deutsche krebshilfe. Patientenleitlinie. Brustkrebs im fr\u00fchen stadium. Leitlinienprogramm onkologie. In.; 2018."},{"key":"10.1016\/j.ctarc.2026.101200_bib0005","unstructured":"Arbeitsgemeinschaft der wissenschaftlichen medizinischen fachgesellschaften e. V., der deutschen krebsgesellschaft e. V. und der stiftung deutsche krebshilfe. Patientenleitlinie. Metastasierter brustkrebs. Leitlinienprogramm onkologie. In.; 2018."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0006","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-020-05657-8","article-title":"Healthcare providers\u2019 adherence to breast cancer guidelines in Europe: a systematic literature review","volume":"181","author":"Ni\u00f1o de Guzm\u00e1n","year":"2020","journal-title":"Breast. Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0007","first-page":"177","article-title":"Assessing the feasibility of a virtual tumor board program: a case study","volume":"59","author":"Shea","year":"2014","journal-title":"J. Heal. Manag."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101200_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153206","article-title":"Differences in breast cancer survival between public and private care in New Zealand: which factors contribute?","volume":"11","author":"Tin Tin","year":"2016","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0009","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/tbj.13231","article-title":"Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: results from the prospective multicenter BRENDA II study","volume":"25","author":"Leinert","year":"2019","journal-title":"Breast. J."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0010","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10549-011-1935-y","article-title":"Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival\u2014a retrospective multi-centre cohort study","volume":"132","author":"Schwentner","year":"2012","journal-title":"Breast. Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2772-y","article-title":"For the BSG: comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8935 patients","volume":"142","author":"Wolters","year":"2013","journal-title":"Breast. Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-015-3484-2","article-title":"Guidelines are advantageous, though not essential for improved survival among breast cancer patients","volume":"152","author":"Wolters","year":"2015","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101200_bib0013","unstructured":"BRE-BY-MED \/digiOnko. https:\/\/www.med.uni-wuerzburg.de\/en\/epidemiologie\/forschung\/projekte\/versorgungsforschung\/bre-by-med-digionko\/."},{"key":"10.1016\/j.ctarc.2026.101200_bib0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40814-019-0541-3","article-title":"Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the \"Breast cancer care for patients with metastatic disease\" (BRE-4-MED) registry","volume":"6","author":"Stangl","year":"2020","journal-title":"Pilot. Feasibil. Stud."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101200_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12885-025-13548-8","article-title":"Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study","volume":"25","author":"Brandstetter","year":"2025","journal-title":"BMC. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101200_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102450","article-title":"Evolution of medical approaches and prominent therapies in breast cancer","volume":"14","author":"Duan","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","article-title":"Metastatic breast cancer: the treatment challenge","volume":"8","author":"Jones","year":"2008","journal-title":"Clin. Breast. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101200_bib0018","first-page":"2759","article-title":"Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy\u2014results from the prospective multi-center study BRENDA II","volume":"24","author":"Schwentner","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0019","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10549-018-4659-4","article-title":"Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States","volume":"168","author":"Poorvu","year":"2018","journal-title":"Breast. Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101200_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.6004\/jnccn.2019.7373","article-title":"Guideline-concordant treatment among elderly women with HER2-positive metastatic breast cancer in the United States","volume":"18","author":"Vyas","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101200_bib0021","first-page":"259","article-title":"Disparities in guideline-concordant initial systemic treatment in women with HER2-negative metastatic breast cancer: a SEER-medicare analysis","volume":"13","author":"Vyas","year":"2021","journal-title":"Breast. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101200_bib0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2018.7004","article-title":"Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study","volume":"16","author":"LeMasters","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101200_bib0023","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2018.7272","article-title":"Population-based study on cancer subtypes, guideline-concordant adjuvant therapy, and survival among women with stage I-III breast cancer","volume":"17","author":"Hsieh","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101200_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/1055-9965.EPI-20-0985","article-title":"Determinants of guideline-discordant breast cancer care","volume":"30","author":"McDougall","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12282-016-0701-8","article-title":"Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II","volume":"24","author":"St\u00fcber","year":"2017","journal-title":"Breast. Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101200_bib0026","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdp028","article-title":"Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?","volume":"20","author":"Simmons","year":"2009","journal-title":"Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr3630","article-title":"Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives","volume":"16","author":"Criscitiello","year":"2014","journal-title":"Breast. Cancer Res."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101200_bib0028","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: Afvmerican society of clinical oncology clinical practice guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101200_bib0029","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ctrv.1999.0161","article-title":"Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer","volume":"26","author":"Stockler","year":"2000","journal-title":"Cancer Treat. Rev."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101200_bib0031","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","article-title":"Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline","volume":"32","author":"Partridge","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0032","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2000.18.2.262","article-title":"Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an eastern cooperative oncology group study","volume":"18","author":"Sledge","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0033","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","volume":"2009","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101200_bib0034","first-page":"791","article-title":"Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the US","volume":"16","author":"Henry","year":"2008","journal-title":"Support. Care Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101200_bib0035","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1245\/s10434-025-18057-3","article-title":"Postmastectomy radiation therapy: an ASTRO\/ASCO\/SSO clinical practice guideline","volume":"32","author":"Jimenez","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101200_bib0036","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0360-3016(92)90565-Y","article-title":"A review of local radiotherapy in the treatment of bone metastases and cord compression","volume":"23","author":"Bates","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2\u20133","key":"10.1016\/j.ctarc.2026.101200_bib0037","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0959-8049(05)80131-5","article-title":"The use of palliative radiotherapy in the management of breast cancer","volume":"28","author":"Maher","year":"1992","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0038","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000338724","article-title":"Radiotherapy of bone metastasis in breast cancer patients - current approaches","volume":"7","author":"Feyer","year":"2012","journal-title":"Breast Care"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101200_bib0039","first-page":"e3286","article-title":"Pain management in metastatic bone disease: a literature review","volume":"10","author":"Ahmad","year":"2018","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101200_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101200_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101200_bib0042","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/thorax-2022-219784","article-title":"British thoracic society guideline for pleural disease","volume":"78","author":"Roberts","year":"2023","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101200_bib0043","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101200_bib0044","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2023.03.028","article-title":"European society of breast cancer specialists\/advanced breast cancer global alliance quality indicators for metastatic breast cancer care","volume":"187","author":"Cardoso","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101200_bib0045","series-title":"UpToDate","article-title":"Clinical features, diagnosis, and staging of newly diagnosed breast cancer","year":"2023"},{"key":"10.1016\/j.ctarc.2026.101200_bib0046","unstructured":"American Cancer Society. Hormone therapy for breast cancer. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment\/hormone-therapy-for-breast-cancer.html."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","article-title":"Updated UK recommendations for HER2 assessment in breast cancer","volume":"68","author":"Rakha","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101200_bib0048","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101200_bib0049","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clbc.2012.11.001","article-title":"Vapiwala N: incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment","volume":"13","author":"Berman","year":"2013","journal-title":"Clin. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2026.101200_bib0050","unstructured":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut. Krebs in Deutschland f\u00fcr 2019\/2020. In., vol. 14. Ausgabe. Berlin; 2023."},{"key":"10.1016\/j.ctarc.2026.101200_bib0051","unstructured":"National Cancer Institute. Cancer statistics: fact sheets, cancer of the breast incidence and moortality, SEER incidence. Surveillance epidemiology and end results. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html#incidence-mortality."},{"key":"10.1016\/j.ctarc.2026.101200_bib0052","article-title":"Metastasis patterns and prognosis in young breast cancer patients: a SEER database analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101200_bib0053","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10198-016-0849-3","article-title":"Access, use, and challenges of claims data analyses in Germany","volume":"18","author":"Neubauer","year":"2017","journal-title":"Eur. J. Health Econ."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101200_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph14121543","article-title":"Individual data linkage of survey data with claims data in Germany-an overview based on a cohort study","volume":"14","author":"March","year":"2017","journal-title":"Int. J. Env. Res Publ. Health"},{"key":"10.1016\/j.ctarc.2026.101200_bib0055","unstructured":"digiOnko https:\/\/www.digionko-bayern.de\/."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:47:23Z","timestamp":1780919243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":55,"alternative-id":["S2468294226001115"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101200","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of quality indicators to assess the prevalence of guideline adherence in a german cohort of patients with advanced or metastatic breast cancer: Results of the BRE-BY-MED study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101200"}}